search
Back to results

Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response.

Primary Purpose

Female Infertility

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Clomiphene citrate
Gonadotropins
Sponsored by
University of Athens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Female Infertility focused on measuring Clomiphene citrate, IVF, Pregnancy Rates, Ovarian Reserve

Eligibility Criteria

20 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women with poor response to ovarian stimulation. The definition of poor response was based on the presence of at least one of the following criteria: Age > 40 years old, day 2 FSH >9.5 mIU/ml, AMH < 2ng/ml ,at least one previous COH with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of HCG.

Exclusion Criteria:

  • All other women that do not fulfill the above mentioned criteria

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Clomiphene citrate

    Gonadotropins

    Arm Description

    Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.

    Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.

    Outcomes

    Primary Outcome Measures

    Clinical pregnancy
    At the completion of the ovarian stimulation patients that will proceed to transfer and have a positive pregnancy test will have sonographic evaluation for confirmation of clinical pregnancy.

    Secondary Outcome Measures

    Full Information

    First Posted
    September 9, 2014
    Last Updated
    September 9, 2014
    Sponsor
    University of Athens
    Collaborators
    Lito Maternity Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02237755
    Brief Title
    Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response.
    Official Title
    Prospective Randomized Trial on the Effect of Clomiphene Citrate Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and Pregnancy Outcome.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2014
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2014 (undefined)
    Primary Completion Date
    November 2014 (Anticipated)
    Study Completion Date
    December 2015 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Athens
    Collaborators
    Lito Maternity Hospital

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Coadministration of various drugs used for ovarian stimulation can increase the efficiency of IVF especially in poor responders. The investigators hypothesize that ovarian response of those patients could improve by using combination of clomiphene citrate with gonadotropins in infertile women with poor response to gonadotrophin administration only.
    Detailed Description
    Patients diagnosed with poor ovarian response will be included in the study. The definition of poor response was based on the presence of at least one of the following criteria: Age > 40 years old, day 2 FSH >9.5 mIU/ml, AMH < 2ng/ml ,at least one previous COH with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of HCG. All patients will be counseled regarding their prognosis and other treatment options including oocyte donation as well as adoption were also presented and discussed in detail. Early follicular phase FSH, estradiol (E2) and Anti-Mullerian Hormone (AMH) will be measured prior to the initiation of treatment. Women in the Clomiphene group will receive 100-150 mg of Clomiphene citrate once per day for 5 days in combination with gonadotropins according to short GnRH-antagonist protocol: all women will have measurements of serum FSH and estradiol and a pelvic sonogram on the second day of their cycle. Providing that serum FSH is < 17 mIU/ml and estradiol is < 70 pg/ml on day 2 , ovarian stimulation will be initiated with 100-150 mg of Clomiphene citrate in combination with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH. All patients will be re-evaluated on day 5 of the stimulation, and dosage adjustments will be made and the antagonists (Cetrorelix or ganirelix 0.25 mg/day) will be initiated. When at least 2 follicles reach an average diameter of 17 mm, final oocyte maturation will be triggered with 10,000IU of hCG ( Pregnyl, Organon, Greece Inc.). Oocyte retrieval will be performed 34 to 36 hours later. All patients will undergo ICSI. Patients with successful fertilization will have embryo transfer under sonographic guidance on day 3 after retrieval. Women in the Gonadotropin group will receive only gonadotropins according to short GnRH-antagonist protocol as it was mentioned above.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Female Infertility
    Keywords
    Clomiphene citrate, IVF, Pregnancy Rates, Ovarian Reserve

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    50 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Clomiphene citrate
    Arm Type
    Active Comparator
    Arm Description
    Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
    Arm Title
    Gonadotropins
    Arm Type
    Active Comparator
    Arm Description
    Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
    Intervention Type
    Drug
    Intervention Name(s)
    Clomiphene citrate
    Other Intervention Name(s)
    Clomiphene citrate 50 mg/tab, Cerpafar 50 mg/tab
    Intervention Description
    clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
    Intervention Type
    Drug
    Intervention Name(s)
    Gonadotropins
    Other Intervention Name(s)
    Menopur 75IU , Gonal
    Intervention Description
    All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
    Primary Outcome Measure Information:
    Title
    Clinical pregnancy
    Description
    At the completion of the ovarian stimulation patients that will proceed to transfer and have a positive pregnancy test will have sonographic evaluation for confirmation of clinical pregnancy.
    Time Frame
    14 days after embryo transfer

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Women with poor response to ovarian stimulation. The definition of poor response was based on the presence of at least one of the following criteria: Age > 40 years old, day 2 FSH >9.5 mIU/ml, AMH < 2ng/ml ,at least one previous COH with less than 3 oocytes retrieved, at least one cancelled attempt due to poor response, estradiol less than 500 pg/ml on the day of HCG. Exclusion Criteria: All other women that do not fulfill the above mentioned criteria
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Nikos Vlahos, MD
    Phone
    30 210 7286000
    Email
    nikosvlahos@med.uoa.gr
    First Name & Middle Initial & Last Name or Official Title & Degree
    Olga Triantafyllidou, MD
    Phone
    30 2107485591
    Email
    triantafyllidouolga@yahoo.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nikos Vlahos, Assoc. Prof.
    Organizational Affiliation
    University of Athens, 2nd Department of Obstetrics and Gynecology
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Olga Triantafyllidou, MD
    Organizational Affiliation
    University of Athens School of Medicine
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response.

    We'll reach out to this number within 24 hrs